Half-Year 2022 Financial Performance

H1 Sales in Small Molecules Sales impacted by phasing of deliveries - Sales expected in H1 delayed into H2 due to phasing of major shipments to contracted customers CDMO business model offers flexibility to customers on pick-up timings of contracted product Fully contracted make-to-order production mitigates risk of inventory obsolescence High utilization of asset base and underlying divisional business remains strong Lonza 14

View entire presentation